Real-world studies have shown that a significant proportion of patients with kidney impairment receive an unlicensed DPP4i dose1,2.


47%
of DPP4i patients (excluding patients treated with TRAJENTA®) with moderate to severe CKD were on an unlicensed dose according to claims data (n=380) analysed in a US study*2

TRAJENTA® can help you in your daily practice by:

TRAJENTA® offering a simple way to keep your patients on a licensed DPP4i dose
Offering a simple way to
keep your patients on a
licensed DPP4i dose

(when the appropriate 5 mg QD
dose is administered)3
TRAJENTA® helping avoid cumbersome conversations around dose adjustment
Helping
avoid cumbersome
conversations around dose
adjustment4
TRAJENTA® not requiring any additional drug-related kidney function monitoring
Not requiring any
additional drug-related
kidney function monitoring3

*The objective of this retrospective database study was to describe real-world patterns of DPP4i use and to assess concordance with PI recommended dosing among patients with T2D and moderate to severe CKD (Stage 3b-5; indicated by eGFR value <45 mL/min/1.73m2) treated with sitagliptin, saxagliptin, or linagliptin. The study used Quintiles’ electronic medical records (Q-EMR) linked to administrative claims from Truven’s MarketScan database 2010-2014 in the US; 492 DPP4i patients with moderate to severe CKD were identified (323 on sitagliptin, 57 on saxagliptin, 112 on linagliptin).

CKD: Chronic kidney disease; eGFR: Estimated glomerular filtration rate; ESRD: End-stage renal disease; QD: Once daily.